Contact Us

Veterinary Applications

The ROP technology has many applications in veterinary medicine. OVM is looking for licensing partners with development and commercialisation capabilities in animal health.
Applications in animal health

Oncology

Veterinary Applications of ROP technology
Osteosarcoma is the most common primary bone tumour in dogs and in humans. Inhibition of survivin (SVN, an inhibitor of apoptosis antigen) which is highly expressed in both canine osteosarcoma and lymphoma, has been shown to decrease tumour volume. In addition, there is over 90% homology of human SVN and dog SVN.
Oxford Vacmedix’s lead vaccine, OVM-200 targets survivin as its antigen and is in Phase 1 human trials for prostate, ovarian and NSCLC. Initial results show an excellent safety profile and a very strong dual mode of action with both T cell-mediated and humoral antibody immune responses.
Dog

Viral Indications

Overlapping synthetic peptides for viral infections were originally invented by Professor Jiang at Harvard and have been shown to work well. Further development of the technology to produce Recombinant Overlapping Peptides (ROP) has many applications for viral indications.

In response to the Covid pandemic Oxford Vacmedix designed, synthesised, purified and tested an ROP Covid-19 vaccine in mice in just 4 months, showing a strong immune response. Individual peptides easily added/substituted for efficacy versus different viral strains. Other targets could include specific foot-and-mouth (FMD) VP1/VP2 antigens.

ROPs offer a triple mode of action against viral infections:

  • Stimulate CD4 and CD8 T-cells to drive immunogenic response.
  • Generate antibodies that block viral binding to receptor.
  • Generate antibodies that block viral fusion to host cell membrane.

In addition, ROPs do not risk incompletely inactivating the virus, have very low production cost and are highly stable, so do not need ultra-low temp storage.

Diagnostic Packaging
The AMR test will fulfil a real need in a growing market. OVM is looking for partners to commercialise the kit.

Bacterial Indications

Bovine tuberculosis (TB) is a serious animal health issue –  endemic in many countries and is also transmissible to humans. Changzhou Biotech, under license from OVM has already developed an ELISPOT diagnostic test for human TB which has regulatory approval from the NPMA in China. The test is fast, accurate and very cost-competitive and is one of only two proprietary TB-ELISPOT kits with global freedom to operate. The CBIG TB test has significant cost advantages arising from production of the recombinant assay.

The ROP technology can potentially be developed into a more efficacious peptide-based bovine TB vaccine. Further advantages of a ROP vaccine are that it would be highly immunogenic with multi-mode of action, could be engineered not interfere with TB skin test by avoiding PPD antigens and could target multiple m. bovis antigens.
Cow
en_GBEnglish
en_GBEnglish